Romaco completes virtual FAT for a blister machine
Despite current travel restrictions, the machine manufacturer manages to perform factory acceptance tests (FATs) via a live stream at its manufacturing facility.
Romaco is responding to the corona crisis by taking new approaches with the factory acceptance tests for its machines. The first Romaco Noack blister machine for a pharmaceutical producer in southern China has now passed its virtual FAT, which was carried out via a live stream.
In the light of current travel restrictions due to the COVID-19 pandemic, the pharmaceutical machinery manufacturer's customers are not allowed to attend the factory acceptance tests for their new equipment in person. Romaco has, therefore, begun carrying out FATs via a live stream or a video conferencing facility instead.
The first live remote FAT for a Noack blister machine was recently completed successfully at the Romaco manufacturing facility in Karlsruhe (Germany). This machine for a pharmaceutical producer in southern China can now be shipped and put into operation as planned.
The virtual FAT followed exactly the same procedure as its conventional counterpart. According to the FAT report, all tests relevant to production and safety were performed on the machine and streamed live.
Only half a day was required for the virtual acceptance of the Noack 623 blister machine, which will be used to seal ultra-lightweight and almost transparent hard gelatine capsules in aluminium–aluminium blisters. The people responsible at the customer end in China monitored the various functional tests closely during the live broadcast. The project manager in charge at Romaco China was at their side to translate any questions and answers straight away and ensure problem-free communication.
A blister line, complete with cartoner and case packer, is currently being acceptance-tested via a live link for a French manufacturer of contract packaging. Parallel to this, preparations are also underway for the FAT for two Romaco Siebler effervescent packaging lines destined for a pharmaceutical group in the US.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance